Refractory polyarteritis nodosa successfully treated with infliximab

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1371-1373

  Al Bishri, Jamal ^a,b   Le Riche, Nicole ^a,b   Pope, Janet E ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Department of Medicine ^*  (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Infliximab; Polyarteritis nodosa

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LF 150195; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CHRONIC DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYDRONEPHROSIS; LAPAROTOMY; LEG ULCER; LIVEDO RETICULARIS; MONONEUROPATHY; PLANTAR FASCIITIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROTEINURIA; SKIN BIOPSY; SYNOVITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; LEG ULCER; POLYARTERITIS NODOSA; WOUND HEALING;

EID: 22244443649     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
2. Garcia-Porrua C, Gonzalez-Gay MA. Successful response to infliximab in a patient with undifferentiated spondylarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis. Clin Exp Rheumatol 2003;21 Suppl 32:5138.
3. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology Oxford 2002;41:1303-7.
4. Valente R, Conn D. Polyarteritis-polyarteritis nodosa and microscopic polyangiitis. In: Dieppe P, editor. Rheumatology. London: Mosby International; 1998:7.20.1.
5. Bacon PA. Therapy of vasculitis. J Rheumatol 1994;21:788-90.
6. Pall AA, Savage CO. Mechanisms of endothelial cell injury in vasculitis. Springer Semin Immunopathol 1994;16:23-37.
7. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
8. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
9. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
10. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5.
11. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology Oxford 2002;41:1126-32.
12. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8.
13. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003;62:280-1.
14. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.